MESOBLAST LTD(MSB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

MSB.AU MESOBLAST LTD

Market Closed 05-17 16:12:00 AEST

1.09

+0.06

+5.85%

High1.10	Low1.02	Vol6.04M
Open1.03	D1 Closing1.03	Amplitude7.32%
Mkt Cap1.24B	Tradable Cap958.67M	Total Shares1.14B
T/O6.41M	T/O Rate0.68%	Tradable Shares883.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.085,"timestamp":1715926320000,"preClose":1.025,"halted":0,"volume":6038289,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":883565265,"shares":1141241211,"eps":-0.13660050738695717,"marketStatus":"Market Closed","change":0.06,"latestTime":"05-17 16:12:00 AEST","open":1.025,"high":1.095,"low":1.02,"amount":6406579,"amplitude":0.073171,"askPrice":1.095,"askSize":44775,"bidPrice":1.075,"bidSize":41856,"shortable":3,"etf":0,"ttmEps":-0.13660050738695717,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":1.025,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":1.1173236572004484,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/MSB.AU","defaultTab":"news","newsList":[{"id":"2435132403","title":"Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435132403","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2435132403?lang=en_us&edition=fundamental","pubTime":"2024-05-13 13:10","pubTimestamp":1715577020,"startTime":"0","endTime":"0","summary":"One leading broker that would approve of these purchases is Bell Potter. Last month, its analysts retained their speculative buy rating on Mesoblast's shares with a vastly improved price target of $1.40 . This implies potential upside of approximately 36% for investors from current levels. The broker is feeling positive about the company's Remestemcel product and believes that approval could be around the corner for the treatment of children with steroid refractory acute graft versus host disease . Bell Potter explains:  Our best estimate for approval of Remestemcel is mid August 2024. The planned adult study in GvHD has for the moment been postponed pending the outcome of the resubmitted BLA. Valuation is increased from $0.58 to $1.40 eflecting significant changes to revenue forecasts bought about by renewed confidence for a prospective approval for Remestemcel in Paediatric GvHD later this year. A first approval may represent a gateway to a series of label expansions in the ensuing p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/13/insider-still-buying-mesoblast-shares-despite-230-rise-this-year-should-you-buy/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434213380","title":"4 Pharma & Biotech Stocks on the move in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2434213380","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2434213380?lang=en_us&edition=fundamental","pubTime":"2024-05-10 06:12","pubTimestamp":1715292750,"startTime":"0","endTime":"0","summary":"Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and the S&P/ASX Small Ordinaries Accumulation Index was down 3.1%. The Healthcare sector was not immune with the S&P/ASX 300 Healthcare Accumulation Index down 2.3% in April. Despite the subdued markets there was a few companies in the Pharma & Biotech sector that experienced strong share price moves. Below we take a look at four companies whose share prices rallied during the month.The market will now be eagerly awaiting the results from the BLA submission with the r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-april","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-april","is_publish_highlight":false,"gpt_icon":0},{"id":"2432191604","title":"If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!","url":"https://stock-news.laohu8.com/highlight/detail?id=2432191604","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2432191604?lang=en_us&edition=fundamental","pubTime":"2024-05-03 12:33","pubTimestamp":1714710800,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd shares have made stockholders very happy this year. How happy?Well, on 2 January, shares in the S&P/ASX 300 Index biotech company were trading for 31 cents before dipping as low as 26 cents in early February. But by 25 March, Mesoblast shares had rebounded to 33 cents, up 6.5% for the year. And soon after, the share price went ballistic.  Earlier on Friday afternoon, shares were up 3.5% at $1.11 apiece. That's up an eye-watering 258% so far in 2024.  Sticking with the year-to-date gains, however, you could have bought 24,242 Mesoblast shares with an $8,000 investment on 2 January. Today, those same shares would be worth – drum roll please – a whopping $26,909! Here's what's been stoking ASX investor interest. Why are Mesoblast shares going gangbusters?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/03/if-you-invested-8000-in-mesoblast-shares-at-the-beginning-of-2024-guess-how-much-youd-have-now/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432619426","title":"9 ASX All Ords shares elevated to 'strong buy' status in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2432619426","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2432619426?lang=en_us&edition=fundamental","pubTime":"2024-05-02 12:44","pubTimestamp":1714625090,"startTime":"0","endTime":"0","summary":"It was a poor month for S&P/ASX All Ords  shares in April, with a 2.72% fall.But analysts think these nine ASX All Ords shares have a bright future ahead.Market analysts on CommSec upgraded all of them to a strong buy rating last month.The consensus rating on Suncorp shares was upgraded to strong buy on 29 April.Goldman Sachs has a buy rating and a 12-month share price target of $17.54 on the ASX All Ords banking and insurance stock.Silver Lake shares were upgraded to strong buy on 26 April.Today, the ASX All Ords gold share is trading for $1.42, up 3.04%.Today, the Australian Unity Office Property Fund share price is $1.26, down 1.94%.Today, the Chalice Mining share price is $1.10, down 6.81%.Today, the ASX All Ords tech share is $80.27, down 0.86%.Today, the landfill gas-to-power generation stock is up 3.45% to $3.00.Today the ASX All Ords rare earths share is trading at 33 cents, down 2.99%.The explorer released its quarterly activities report on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/02/9-asx-all-ords-shares-elevated-to-strong-buy-status-in-april/","is_publish_highlight":false,"gpt_icon":0},{"id":"2431332664","title":"Why Aeris Resources, Mesoblast, Pointsbet, and Worley shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2431332664","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2431332664?lang=en_us&edition=fundamental","pubTime":"2024-04-30 12:42","pubTimestamp":1714452125,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is on form again on Tuesday and pushing higher. At the time of writing, the benchmark index is up 0.2% to 7,651.4 points. Four ASX shares that have failed to follow the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/30/why-aeris-resources-mesoblast-pointsbet-and-worley-shares-are-sinking-today/","is_publish_highlight":false,"gpt_icon":0},{"id":"2431389564","title":"Why is the Mesoblast share price taking a dive on Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2431389564","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2431389564?lang=en_us&edition=fundamental","pubTime":"2024-04-30 10:36","pubTimestamp":1714444609,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is under pressure on Tuesday.At the time of writing, the allogeneic cellular medicines developer's shares are down 4% to $1.04.Though, shareholders won't be too disheartened given that its shares remain up over 200% since the start of the year.Investors have been selling the company's shares on Tuesday following the release of two announcements.The first announcement was its quarterly update, which revealed modest royalty receipts of US$1.7 million for the three months ended 31 March. This brings its year to date royalty receipts to US$5.6 million.However, this was nowhere near enough to offset its spending during the quarter. As a result, the company recorded an operating cash outflow of US$11.6 million. This led to Mesoblast ending the period with a cash balance of US$76.4 million.But that shouldn't take away from the many positives that happened during the quarter. This includes some very promising interactions with the US Food and Drugs Administration","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/30/why-is-the-mesoblast-share-price-taking-a-dive-on-tuesday/","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293755","title":"Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293755","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2430293755?lang=en_us&edition=fundamental","pubTime":"2024-04-26 09:27","pubTimestamp":1714094852,"startTime":"0","endTime":"0","summary":"As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 92 stocks from our Fast Growing Companies With High Insider Ownership screener.Operations: APM Human Services International's revenue segments include A$850.01 million from Australia and New Zealand, A$910.37 million from North America, and A$396.49 million from other international markets such as Korea, Singapore, Germany, Switzerland, Spain, and the UK.Navigate through the intricacies of APM Human Services Inter","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w327mR2RaziNsJkbYHHiAg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a9997715da94a925bc3a3ecccf9d032","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w327mR2RaziNsJkbYHHiAg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a9997715da94a925bc3a3ecccf9d032"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-leading-growth-companies-australia-012732475.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429039131","title":"If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!","url":"https://stock-news.laohu8.com/highlight/detail?id=2429039131","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2429039131?lang=en_us&edition=fundamental","pubTime":"2024-04-23 12:05","pubTimestamp":1713845100,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd shares are at it again today.Shares in the ASXbiotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, shares are swapping hands for 86 cents apiece, up 8.2%.While that's a very tidy intraday gain, it pales in comparison to the 160.6% gains delivered by Mesoblast shares over the past month.One month ago today, you could have snapped up the stock for 33 cents a share.Meaning a $6,000 investment last month would now be worth a whopping $15,636.Here's what's been going right for the company.The big moves higher for Mesoblast shares really commenced on 26 March.Shares gained 3.1% the next day and another 12.1% on Thursday 28 March, before the ASX closed for the four-day Easter holiday.Investors began sending the biotech stock soaring following promising news from the US Food and Drug Administration  about the company's remestemcel-L treatment.A first approval may represent a gateway to a series of label expansions in the ensuing period as reflec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/23/if-you-invested-6000-in-mesoblast-shares-a-month-ago-youd-have-15636-now/","is_publish_highlight":false,"gpt_icon":0},{"id":"2426443153","title":"Mesoblast Limited: Back From The Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=2426443153","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426443153?lang=en_us&edition=fundamental","pubTime":"2024-04-11 01:29","pubTimestamp":1712770162,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has been on a major run recently as its cell therapy candidate is back on track towards potential approval.The company has some upcoming potential catalysts in the quarters ahead and is advancing its pipeline on several fronts.However, given the company is headquartered overseas, it garners slight coverage from Wall Street and has consistently disappointed longer-term investors over the years.An analysis around Mesoblast follows in the paragraphs below.Andrii Dodonov/iStock via Getty Images Today, we take a look at Mesoblast Limited . This overseas development company has had a roller coaster ride in the market since the company got a complete response letter, or CRL, from the FDA around its marketing application for its cell therapy candidate \"remestemcel-L,\" also known as Ryoncil, to treat a type of steroid-refractory acute graft versus host disease or sr-aGVHD in children early in August. The rejection triggered a large sell-off in the stock. However, recent positi","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1912122991/image_1912122991.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1912122991/image_1912122991.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4683142-mesoblast-limited-back-from-the-dead","is_publish_highlight":false,"gpt_icon":0},{"id":"2426458624","title":"ASX 200 edges higher aided by iron ore, base metals, and lithium stocks, gold loses its shine","url":"https://stock-news.laohu8.com/highlight/detail?id=2426458624","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2426458624?lang=en_us&edition=fundamental","pubTime":"2024-04-10 15:51","pubTimestamp":1712735511,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200  finished 20.6 points higher at 7,844.8, 0.26% from its session low and 0.31% from its high. In the broader-based S&P/ASX 300 , advancers beat decliners by 163 to 113.The Real Estate Investment Trusts   sector was the best performing sector today, bouncing back after six very weak sessions. The reason for recent weakness is a corresponding rise in bond yields – property stocks hate rising yields!Today's strength is a direct result of a modest pullback in key bond yields overnight in the US.There was a modest pullback in market yields overnight in the US. Also doing well today was the Health Care   sector as Ansell   and Fisher & Paykel Healthcare   were each the beneficiary of positive broker updates .The Resources sector is one of the most volatile sectors on the ASX. Risk, reward, they’re two sides of the same coin for investors in Aussie resources stocks!The respective points of demand and supply of the XJR’s constituents will be more important, and to be fair, they ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/asx-200-edges-higher-aided-by-iron-ore-base-metals-and-lithium-stocks-gold-loses-its-shine","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/asx-200-edges-higher-aided-by-iron-ore-base-metals-and-lithium-stocks-gold-loses-its-shine","is_publish_highlight":false,"gpt_icon":0},{"id":"2426483060","title":"Why Cardno, Mesoblast, Perseus, and Somnomed shares are dropping today","url":"https://stock-news.laohu8.com/highlight/detail?id=2426483060","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2426483060?lang=en_us&edition=fundamental","pubTime":"2024-04-10 11:32","pubTimestamp":1712719952,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.5% to 7,863.6 points. Four ASX shares that have failed to f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/10/why-cardno-mesoblast-perseus-and-somnomed-shares-are-dropping-today/","is_publish_highlight":false,"gpt_icon":0},{"id":"2425587649","title":"4 Pharma & Biotech Stocks on the Move in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2425587649","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2425587649?lang=en_us&edition=fundamental","pubTime":"2024-04-08 15:25","pubTimestamp":1712561140,"startTime":"0","endTime":"0","summary":"The Pharma and Biotech market was relatively buoyant in March      with 49% of share prices in the coverage universe increasing for the month. There was some significant news flow which resulted in a strong uplift in share prices for some companies. Below we take a look at four companies whose share prices rallied strongly during the month.During the month, Osteopore also provided an interim update on the single-arm feasibility clinical trials being conducted in Australia for cranial and long bone reconstruction using polycaprolactone-tricalcium phosphate customised scaffolds. Each study aimed to recruit 5-10 patients, however the long bone construction trial has now been closed with the recruitment of only 2 patients with patient recruitment proving difficult. The cranial reconstruction trial is now complete with 9 patients participating. 3 patients have reached the post-surgery milestone of 24 months, 1 is at 18 months and 5 are between 1 and 9 months. The study has shown that the cu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-march","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-march","is_publish_highlight":false,"gpt_icon":0},{"id":"2425980330","title":"Mesoblast Could Now Generate Meaningful FY 2025 Revenue -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2425980330","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2425980330?lang=en_us&edition=fundamental","pubTime":"2024-04-08 12:49","pubTimestamp":1712551740,"startTime":"0","endTime":"0","summary":"0448 GMT - Mesoblast keeps its speculative buy rating from Bell Potter despite its recent share-price surge, with analyst John Hester flagging the potential for meaningful revenue generation in fiscal 2025. Hester writes in a note to clients that the U.S. FDA has reinvigorated the approval process for pediatric use of Mesoblast's Remestemcel-L steroid-refractory acute graft versus host disease treatment. Shares in the regenerative-medicine developer have almost trebled in value in 2024, but Hester estimates FDA approval in mid-August and sees more upside. He lifts his fiscal 2025 revenue forecast to US$41.6 million, from US$7.6 million. Target price rises to A$1.40 from A$0.58. Shares are up 4.05% at A$0.90. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2425087639","title":"Top brokers name 3 ASX shares to buy next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2425087639","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2425087639?lang=en_us&edition=fundamental","pubTime":"2024-04-07 05:30","pubTimestamp":1712439000,"startTime":"0","endTime":"0","summary":"It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:. Analysts at UBS have retained their buy rating on this wine giant's shares with an improved price target of $15.25. This follows confirmation that the Chinese Ministry of Commerce  is removing tariffs from Australian wine imports into China. According to the note, UBS was pleased with the news and believes that Treasury Wine's shares now deserve to trade on higher earnings multiples. Especially given that this news increases its addressable market. Its analysts have also lifted their earnings estimates to reflect the news and higher margin assumptions for its premium wine. The Treasury Wine share price ended the week at $12.86.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/07/top-brokers-name-3-asx-shares-to-buy-next-week-211/","is_publish_highlight":false,"gpt_icon":0},{"id":"2425645597","title":"Why is everyone talking about Mesoblast shares?","url":"https://stock-news.laohu8.com/highlight/detail?id=2425645597","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2425645597?lang=en_us&edition=fundamental","pubTime":"2024-04-06 02:30","pubTimestamp":1712341800,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd shares have certainly been garnering plenty of attention of late. That's come amid some astonishing recent daily share price moves for the ASXbiotech company. How astonishing?On 26 March Mesoblast shares closed the day up an eye-popping 45.5% to close at 48 cents apiece, having reached intraday highs of 52 cents. But ASX investors weren't done yet. The next day the biotech stock gained 3.1% followed by a 12.1% gain on 28 March, to close out last month on a bang. And if you think those are some big moves, then you must not have been watching the boards on Tuesday, 2 April, when the ASX re-opened following the four-day Easter holiday break. Any guesses on how much Mesoblast shares gained on Tuesday?I won't leave you hanging. The biotech stock rocketed an astounding 71.2% on the first trading day of April, closing the day at 95 cents apiece, with intraday prices as high as 96 cents!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/06/why-is-everyone-talking-about-mesoblast-shares/","is_publish_highlight":false,"gpt_icon":0},{"id":"2425048833","title":"Why the Mesoblast share price can rise another 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425048833","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2425048833?lang=en_us&edition=fundamental","pubTime":"2024-04-05 11:36","pubTimestamp":1712288215,"startTime":"0","endTime":"0","summary":"While approval is by no means guaranteed, Bell Potter is feeling a lot more confident now. Approval would be good for investors for a couple of reasons. One is that it means meaningful revenue generation may not be far away. The other is that it could open the door to further use cases in the near future. The broker concludes:  Our best estimate for approval of Remestemcel is mid August 2024. The planned adult study in GvHD has for the moment been postponed pending the outcome of the resubmitted BLA. Valuation is increased from $0.58 to $1.40 reflecting significant changes to revenue forecasts bought about by renewed confidence for a prospective approval for Remestemcel in Paediatric GvHD later this year. A first approval may represent a gateway to a series of label expansions in the ensuing period as reflected in the share price movement in recent days.  The Mesoblast share price remains down 11% over the last 12 months despite its recent surge.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/05/why-the-mesoblast-share-price-can-rise-another-60/","is_publish_highlight":false,"gpt_icon":0},{"id":"2425304888","title":"Brokers name 3 ASX shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2425304888","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2425304888?lang=en_us&edition=fundamental","pubTime":"2024-04-05 11:22","pubTimestamp":1712287373,"startTime":"0","endTime":"0","summary":"It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/05/brokers-name-3-asx-shares-to-buy-now-64-2/","is_publish_highlight":false,"gpt_icon":0},{"id":"2424539948","title":"Why Mesoblast, Regis Resources, Westgold, and WiseTech shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2424539948","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2424539948?lang=en_us&edition=fundamental","pubTime":"2024-04-03 11:57","pubTimestamp":1712116631,"startTime":"0","endTime":"0","summary":"It has been a difficult session for theS&P/ASX 200 Index(ASX: XJO). In afternoon trade, the benchmark index has followed Wall Street's lead and dropped deep into the red. At the time of writing, the b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/03/why-mesoblast-regis-resources-westgold-and-wisetech-shares-are-sinking-today/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesoblast.com","stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.4467},{"period":"3month","weight":2.807},{"period":"6month","weight":1.8933},{"period":"1year","weight":-0.0565},{"period":"ytd","weight":2.5}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.65,"avgChangeRate":0.040448},{"month":2,"riseRate":0.55,"avgChangeRate":0.057879},{"month":3,"riseRate":0.35,"avgChangeRate":0.096272},{"month":4,"riseRate":0.55,"avgChangeRate":0.006376},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.057738},{"month":6,"riseRate":0.684211,"avgChangeRate":0.077382},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.043631},{"month":8,"riseRate":0.473684,"avgChangeRate":0.054639},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.008146},{"month":10,"riseRate":0.578947,"avgChangeRate":0.035505},{"month":11,"riseRate":0.526316,"avgChangeRate":-0.01593},{"month":12,"riseRate":0.6,"avgChangeRate":0.038258}],"exchange":"ASX","name":"MESOBLAST LTD","nameEN":"MESOBLAST LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MESOBLAST LTD(MSB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MESOBLAST LTD(MSB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MESOBLAST LTD,MSB.AU,MESOBLAST LTD股票,MESOBLAST LTD股票老虎,MESOBLAST LTD股票老虎国际,MESOBLAST LTD行情,MESOBLAST LTD股票行情,MESOBLAST LTD股价,MESOBLAST LTD股市,MESOBLAST LTD股票价格,MESOBLAST LTD股票交易,MESOBLAST LTD股票购买,MESOBLAST LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MESOBLAST LTD(MSB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MESOBLAST LTD(MSB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction